In summary, consistent with the results of study 1, BE administration improved genetically induced obesity and its related metabolic syndromes by the activation of TGR5 and FXR via the regulation of the GM and the plasma BA pool. The gene discussed is GPBAR1; the disease is obesity due to melanocortin 4 receptor deficiency.